Arcticzymes Technologies Asa · OSL:AZT
Arcticzymes Technologies Asa — Q4 2022 Earnings Presentation
19 slides from Arcticzymes Technologies Asa's earnings presentation, February 2023
Slide 1: Q4 2022 Presentation
Q4 2022 Presentation Børge Sørvoll February 2023
Slide 2: Agenda
Agenda 1 Highlights – Q4 2022 2 Financials 3 Business Update - R&D - Operation - Commercial
Slide 3: Highlights
Highlights
Slide 4: Highlights Q4 2022
Highlights Q4 2022 Challenging fourth quarter Quarterly sales Walked away on In-licensed 28.2 MNOK M&A deal after DD exclusive novel process DNA assembly technology EBITDA Launched 3 new performance products 1.3 MNOK 4
Slide 5: Sales
Sales
Slide 6: Sales per area: Molecular Tools
Sales per area Commercial 35 30 25 Molecular Tools Sales in MNOK 20 ✓ Quarterly sales 9.0 MNOK 15 ✓ Accounts for 31% of total Q4 sales 10 ✓ Research and Diagnostics contribution to Q4 sales were 15% and 16%, respectively 5 ✓ Research – no large orders from key customers in Q4 ✓ Diagnostics – “no” co
Slide 7: Covid related sales
Sales Commercial 18 16 14 Covid related sales 12 Sales in MNOK 10 ✓ 0 MNOK in Covid related sales for Q4 8 ✓ 15 MNOK in sales for 2022, where Q1 2022 had 14 6 MNOK ✓ Headwind for sale of COD Ung moving forward 4 ✓ Endemic state where we expect to achieve only 2 marginal sales from Corona-virus 0 Q1
Slide 8: Sales per area: Biomanufacturing
Sales per area Commercial 25 20 Biomanufacturing 15 Sales in MNOK ✓ Quarterly sales 19.2 MNOK (65% growth) 10 ✓ Accounts for 69% of total Q4 sales ✓ Upturn in sales following pandemic continues 5 ✓ 60% growth in sales for the year ✓ Drug Master File (DMF) submission for SAN HQ to the U.S. FDA is pro
Slide 9: 12 month rolling average quarterly sales
12 month rolling average quarterly sales Growth story is still intact 40 Sales development 35 Sales development ex Covid-19 …..but Q4 had a negative impact on story 30 Nothing fundamentally has changed even though we experienced Q4 headwinds 25 MNOK 20 Uncertainty on short term customer behaviour 15
Slide 10: Business Updates: Geographical Sales Contribution
Business Updates Commercial Geographical Sales Contribution Americas EMEA APAC 2021 39 % 48 % 13 % 2022 Americas EMEA APAC 44 % 45 % 11 % Q4 Americas EMEA AP. 2022 49 % 42 % 9% 10
Slide 11: Currency impact
USDNOK Currency impact 11 Tailwinds in currency 10,5 10 Majority of revenues are in foreign currency 51% in USD and 49% in EURO for Q4 9,5 68% in USD and 31% in EURO for 2022 9 Currency effect on P&L 8,5 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Finance -0.7 MNOK in Q4 (12M 2022: +1.8 MNOK) EU
Slide 12: Expenses and profitability
Expenses and profitability
Slide 13: Organisation
Organisation Aligned with strategic growth Number of employees 31.12 70 Ambition and strategy has been to grow company organically 60 30% increase in employees from 2021 to 2022 61 employees per 31.12.2022 50 40 Administration 9% 30 R&D Business 39 % development and marketing 20 21 % 10 QA and 0 reg
Slide 14: Extraordinary items Q4
Extraordinary items Q4 Reversals and capitalisation Q4 Adjusted one-offs in Q4 (Amounts in MNOK) 2022 Adjusted M&A due diligence, MNOK 2.8 Sales revenues 28,2 28,2 ESG/HRM support, MNOK 0.4 Other revenues 0,3 0,3 Bonus accruals reversed, MNOK -1.9 Sum revenues 28,4 28,4 DMF capitalised – reversed MN
Slide 15: Profitability and expenses
Profitability and expenses Investments in organic and inorganic growth influences our figures EBITDA 60 Sales EBITDA Q4 - MNOK 1.3 vs 20.9 50 2022 - MNOK 41.5 vs 61.6 40 Expenses increased by 7.9 MNOK in Q4 MNOK 30 One-offs, reversals, personnel and external support 20 Full year expenses: 91 MNOK vs
Slide 16: Cash flow
Cash flow +6 MNOK in positive cash flow for Q4 250 Net Cash (MNOK) 30 240 Changes in Cash (MNOK) 25 230 220 20 Changes in cash (MNOK) 210 Net Cash (MNOK) 200 15 190 10 180 170 5 160 150 Q1 2021 Q2 2021 Q3 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 16
Slide 17: Outlook
Outlook
Slide 18: Outlook 2023 and Beyond
Outlook 2023 and Beyond Committed to achieve its strategic goals through organic and inorganic growth. Fundamental business remains strong and therefore we expect annual sales to grow from 2022 to 2023. Capitalise on organic investments carried out in 2022 through productive organisation while havin
Slide 19: Thank you Q&A Session
Thank you Q&A Session arcticzymes.com
ArcticZymes Technologies — Q4 2022 Earnings Presentation on 6ix